Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Thursday, August 13, 2026

Snapshot: Aug 13, 2026 · 6:00 PM 100 stocks analyzed

Strong Up Day

Thu, Aug 13, 2026 Broad Rally High

Healthcare stocks led a broad market rally with the S&P 500 up 1.15% and NASDAQ up 1.73%, while high dispersion saw 50 stocks move >25% as earnings season intensified.

55% Broad-based rally with tech and small caps outpacing: S&P 500 +1.15%, NASDAQ +1.73%, Russell 2000 +1.71%, and VIX down 1.8% signaled risk-on sentiment across all major indices, with NASDAQ-100 leading at +2.42% as investors rotated into growth and small-cap sectors simultaneously.
30% Healthcare sector dominance among gainers with earnings-driven spikes: Healthcare stocks claimed 50% of the top 50 gainers, including massive beats from HCTI (+27.87% on 322% gross profit surge), OMER (+26.68% on YARTEMLEA sales tripling), and ETON (+19.16% on record $37.6M revenue), offsetting a handful of biotech disappointments like HUMA (-16.89% on revenue miss) and INV (-43.09% on weak guidance).
15% High single-stock dispersion with earnings beats and misses creating extreme edges: 50 stocks moved >25%, driven by earnings announcements across software (WDAY +17.8% on Silver Lake buyout talks), small-cap industrials (ARX +40.34% on $4B Thoma Bravo acquisition, A2Z +24.91% on 73.65% revenue beat), and biotech recovery plays (CAPR +61.55% on positive Phase 3 reversal, LEXX +31.74% on PegBio MTA), while losers like LESL (-40.33% guidance cut) and CLBT (-29.54% on missed targets) showed earnings volatility cutting both ways.

Healthcare drove 50% of gainers 5 names returned after long absences ARX — first appearance PMA — first appearance

Market Regime

Thu, Aug 13, 2026 Risk-On conf: medium macro · prototype

+52

Tailwind −100 … +100 · + tailwind / − headwind

VIX14.6 p3 Drawdown0.0% Held9d · established SinceAug 3

Top drivers: VIX percentile ▲ S&P vs 20d avg ▲ S&P vs 50d avg ▲

processId: history-market-regime

Market Indexes

Thu, Aug 13, 2026 13

S&P 500

7,798.99

+89.03

+1.15%

Dow Jones

53,839.99

−45.11

-0.08%

NASDAQ Composite

26,803.03

+454.68

+1.73%

NASDAQ 100

30,084.50

+711.17

+2.42%

DJ US Total Market

77,313.23

+1,026.15

+1.35%

Russell 1000

4,252.62

+55.82

+1.33%

S&P MidCap 400

3,914.43

+80.04

+2.09%

Russell 2000

3,052.85

+51.30

+1.71%

Russell 2500

1,305.33

+5.65

+0.43%

Russell 3000

4,439.88

+58.96

+1.35%

Nasdaq Financial-100

7,677.81

+82.62

+1.09%

NIFTY 50

24,395.85

−174.80

-0.71%

VIX

14.63

−0.27

-1.81%

Biggest Gainers

Thu, Aug 13, 2026 50

DFSCW

DEFSEC Technologies Inc.Industrials

$0.03+$0.02

+91.5%

AKAN

Akanda Corp.Healthcare

$5.03+$4.61

+91.5%

NASDAQ · Mkt cap $2.6 M

Akanda's subsidiary First Towers & Fiber completed a 200 km fiber network expansion that increases recurring revenue, likely triggering the 91% gain as the market responds to concrete infrastructure growth in the telecom sector.

The headline establishes that Akanda's 100% owned subsidiary First Towers & Fiber has completed a significant fiber network expansion of 200 kilometers and explicitly ties this to increased recurring revenue. This is a material operational milestone for a telecommunications infrastructure company, as fiber network buildout directly translates to revenue-generating assets and customer acquisition capacity. The timing of the announcement on August 13 aligns precisely with the stock's move on the same date, suggesting the market is pricing in the value creation from this infrastructure completion. A near-doubling in share price on the back of a single operational achievement of this scale suggests either prior undervaluation, significant short positioning, or market enthusiasm for the company's telecom infrastructure strategy. The news does not provide financial metrics, revenue figures, or contract details, so the precise magnitude of the revenue increase remains unclear from the available information.

DFSC

DEFSEC Technologies Inc.Industrials

$2.31+$1.12

+83.6%

NASDAQ · Mkt cap $5.8 M

DEFSEC Technologies announced Q3 Fiscal 2026 results on August 13, which likely drove the +83.58% gain, though the actual financial details in the headline are truncated and unavailable for review.

The timing alignment between the earnings announcement (released at 11:29 UTC on August 13) and the same-day massive rally strongly suggests the quarterly results were the primary catalyst. An 83% single-day jump is a dramatic move typically reserved for significant positive surprises, contract wins, or major guidance raises in small-cap stocks. However, the provided headline text cuts off mid-sentence after "This a…" and does not disclose the actual earnings figures, revenue performance, margin trends, or forward guidance that would normally explain such a sharp reaction. Without access to the full earnings release details, we cannot confirm whether the move reflects a genuine earnings beat, improved outlook, major customer wins, or other specific operational achievements. For a micro-cap NASDAQ stock like DFSC, volatility and momentum trading can amplify moves, but an 83% surge almost certainly requires concrete positive news rather than technical factors alone.

BBBY.WT

Bed Bath & Beyond, Inc. WT

$0.58+$0.26

+81.3%

CAPR

Capricor Therapeutics IncHealthcare

$4.23+$2.57

+61.6%

NASDAQ · Mkt cap $464 M

Capricor announced positive Phase 3 results for Deramiocel and a Biologics License Application under active FDA review, reversing two days of steep analyst downgrades triggered by an earlier AdCom setback.

On August 12, analyst downgrades cut fair value estimates dramatically from ~$49.44 to ~$4.38 following what appears to be an unfavorable advisory committee meeting on Deramiocel. However, on August 13 the company reported that HOPE-3 Phase 3 results achieved the primary endpoint for upper limb function (p=0.029) and that the BLA is under active FDA review. This represents a material clinical milestone that directly contradicts the recent pessimism and suggests the asset may have a path forward despite the AdCom concern. The 61% gain likely reflects relief buying and reassessment that the program is not dead, though the stock remains well below pre-downgrade levels, indicating continued skepticism about approval odds.

INHD

Inno Holdings Inc.Basic Materials

$10.90+$3.48

+53.5%

NASDAQ · Mkt cap $36 M

No news headlines were found in the last 48 hours for INHD, so the 53.54% gain likely reflects either a delayed market reaction to an untracked announcement, technical trading activity, or retail interest rather than a documented corporate event.

The absence of any Yahoo Finance headlines in the prior 48 hours is notable given the magnitude of the move. INHD gained over 53 percent to reach $10.90, placing it as the sixth biggest gainer on the day, yet no identifiable catalyst appears in the news feed. This suggests several possibilities: the stock may have responded to an announcement made outside typical financial news channels, a short squeeze or technical breakout could have triggered momentum-driven buying, or the move could reflect delayed market pricing of information that was not yet widely syndicated. Without access to press releases, SEC filings, or other primary sources beyond the provided headlines, attributing causation requires speculation rather than fact. Micro-cap and NASDAQ-listed companies like INHD can experience volatile moves on light volume or retail interest, making it difficult to pinpoint a specific fundamental driver without additional data.

DAAQ

Digital Asset Acquisition Corp.Financial Services

$7.26+$3.04

+41.4%

NASDAQ · Mkt cap $239 M

No news headlines were available in the last 48 hours, so the +41.43% gain cannot be traced to a specific announced catalyst. The move may reflect a SPAC-related event, technical positioning, or unindexed market information.

Digital Asset Acquisition Corp. is a SPAC (special purpose acquisition company), a structure prone to sharp price moves disconnected from traditional news cycles. SPA CCs can experience significant volatility around merger announcements, shareholder votes, warrant exercises, redemption deadlines, or de-SPAC events, many of which may circulate on social media or industry channels before or concurrent with formal press releases appearing in major RSS feeds. The 41% single-day gain in the absence of captured headlines suggests either a material event not yet reflected in the monitored news sources, a shift in trader sentiment or technical positioning (particularly common in lower-priced SPACs with retail following), or a delayed indexing of a recent announcement. Without access to real-time filings, press releases, or social media discussion, pinpointing the specific cause is not possible from available data.

DARE

Dare Bioscience IncHealthcare

$1.37+$0.59

+40.4%

NASDAQ · Mkt cap $16 M

Daré Bioscience reported Q2 2026 results showing commercial inflection with its first directly commercialized product Flora Sync LF5 generating revenue in July, alongside progress on DARE to PLAY Sildenafil Cream, triggering the 40% gain as a signal of product commercialization momentum.

The headline directly announces second quarter earnings results paired with concrete commercial milestones: Flora Sync LF5 launched and began generating revenue in July, representing the company's entry into direct commercialization rather than reliance on partnerships. DARE to PLAY Sildenafil Cream is progressing toward national dispensing and initial revenue expected in Q3. For a small-cap women's health biotech company, transition from pipeline stage to actual commercial revenue generation is a material inflection point that typically justifies significant re-rating. The headline language emphasizing "commercial inflection" and a "multi-product strategy" suggests management views this as a transformational moment. The stock's ranking as the eighth biggest gainer indicates broad market recognition of this catalyst on the announcement day.

ARX

Accelerant HoldingsFinancial Services

$19.52+$5.60

+40.3%

NYSE · Mkt cap $4.3 B

Accelerant Holdings surged 40% following announcement of a $4 billion all-cash acquisition by Thoma Bravo and better-than-expected Q2 earnings results with strong premium growth and fee revenue.

The move is directly attributable to two catalysts announced on August 13, 2026. First, Accelerant reported Q2 earnings that beat consensus estimates with a 100% earnings surprise and 30% revenue surprise, driven by strong premium growth and higher fee revenues from its Exchange Services. Second and more significantly, the company announced a definitive agreement to be acquired by private-equity firm Thoma Bravo in an all-cash transaction valued at approximately $4.4 billion. The all-cash nature of the deal eliminates downside risk from financing contingencies or adverse stock market movements, and the acquisition price presumably exceeds the stock's previous trading level by a meaningful margin, which explains the 40% one-day jump. The combination of an earnings beat plus a protective acquisition floor typically drives substantial single-day gains in public equities.

PMA

Ming Shing Group Holdings LimitedIndustrials

$1.62+$0.43

+36.7%

NASDAQ · Mkt cap $18 M

Ming Shing Group announced entry into a stock purchase agreement on August 12, which likely triggered the 36.75% surge as investors reacted positively to the M&A or capital deployment news on August 13.

The company disclosed a stock purchase agreement announcement on August 12, 2026, though the full details were truncated in the headline provided. This type of corporate action—particularly M&A activity, strategic acquisitions, or significant capital deployment—typically drives sharp single-day moves in smaller-cap stocks like PMA, especially if the market views the transaction as accretive, strategically valuable, or evidence of management execution. The one-day lag between announcement (August 12) and peak trading activity (August 13 snapshot) is consistent with news propagation and investor processing time. Without the complete press release text, we cannot confirm specifics such as the target company's identity, transaction value, financing structure, or strategic rationale, but the timing alignment between the announcement and the gain strongly suggests causation rather than coincidence.

NMPAR

NMP Acquisition Corp. Right

$0.20+$0.05

+32.5%

NASDAQ

No news headlines were published in the last 48 hours, so the 32.45% jump cannot be attributed to a disclosed catalyst. The move likely reflects technical trading activity or undisclosed market information related to the SPAC rights structure.

No recent news headlines are available to explain today's move. NMPAR is a rights offering associated with NMP Acquisition Corp., a special purpose acquisition company (SPAC). Rights offerings are inherently volatile instruments with low share counts and tight spreads, making them susceptible to large percentage moves on relatively small absolute dollar volumes. Moves in rights can be driven by technical factors, algorithmic rebalancing, shifts in the underlying SPAC's merger probability or timeline, or accumulated retail interest. Without headline confirmation, we cannot identify a specific catalyst, though any material development in the SPAC's business combination process would be the most plausible structural trigger for sustained moves in its rights component.

LEXX

Lexaria Bioscience Corp.Healthcare

$8.01+$1.93

+31.7%

NASDAQ · Mkt cap $19 M

Lexaria announced a Material Transfer Agreement with PegBio on August 13, a strategic partnership that likely signals progress in its drug delivery platform business and triggered a 31.74% single-day rally.

The headline confirms Lexaria entered into a Material Transfer Agreement with PegBio on the day of the move, which is a concrete corporate development. Material Transfer Agreements typically precede or accompany research collaborations and commercialization discussions. For a biotech company with a drug delivery platform, such an agreement with a partner like PegBio suggests validation of its technology and potential revenue or commercialization pathway. The headline does not provide financial terms, clinical details, or revenue projections, so the magnitude of the deal's value is unclear. Biotech stocks with small floats and promotional technology platforms often exhibit outsized moves on partnership announcements, as they can signal de-risking or near-term monetization. The 31.74% single-day gain ranks LEXX as the 12th biggest gainer, which is substantial but not extraordinary for this sector on partnership news.

LIMN

Iris Acquisition CorpHealthcare

$0.14+$0.03

+31.0%

NASDAQ · Mkt cap $9.4 M

Liminatus Pharma announced a transfer to Nasdaq Capital Market and an extension to regain compliance with minimum bid price requirements, likely triggering relief buying after the stock faced delisting risk.

The headline indicates Liminatus (ticker LIMN) has been in non-compliance with Nasdaq's minimum bid price rule, a serious threat to listing status. The announcement of a transfer to the Nasdaq Capital Market (a lower-tier listing) coupled with an extension to regain compliance suggests the company negotiated a reprieve rather than facing immediate delisting. For a penny stock trading at $0.14, this is material news. Investors holding shares that faced extinction risk may have rushed to buy on relief that the company retains exchange listing and time to recover the stock price. The 31% single-day gain is consistent with a short-squeeze or relief bounce on avoided delisting, though the headline is truncated and does not provide full details of the compliance timeline or remediation plan.

MDXH

MDxHealth SAHealthcare

$0.46+$0.14

+30.6%

NASDAQ · Mkt cap $39 M

MDxHealth reported second-quarter 2026 revenue of $27.2 million with 16% year-over-year growth, likely triggering the 30.56% intraday surge as the earnings announcement and conference call occurred on August 13.

The timing of the 30.56% gain directly coincides with MDxHealth's earnings release and scheduled conference call (4:30 PM EST / 22:30 CET) on August 13. The headline reports second-quarter revenue growth of 16% to $27.2 million, which represents positive top-line momentum. However, the provided snippet does not include net income, guidance, margin trends, or commentary from the call itself—elements that typically drive magnitude and conviction in stock reactions. The substantial jump suggests investors responded favorably to either the growth rate, the absolute revenue level, or forward guidance discussed during the call. Without access to full earnings context (profitability, margins, outlook), we cannot definitively separate whether the move reflects beats on consensus expectations versus a simple positive headline release.

JUNS

Jupiter Neurosciences, Inc.Healthcare

$6.05+$1.39

+30.2%

NASDAQ · Mkt cap $3.7 M

No news headlines were found in the last 48 hours, so the 30% gain cannot be directly attributed to a reported catalyst. The jump was likely driven by technical factors, rumor, or a delayed market reaction to an untracked announcement.

Jupiter Neurosciences experienced a sharp 30% intraday move despite the complete absence of news coverage in the Yahoo Finance RSS feed over the past two days. This disconnect between price action and reported information is notable. For a small-cap neuroscience company, catalysts that typically drive such moves include clinical trial results, regulatory decisions from the FDA, partnership announcements, or insider transactions. Without headlines to anchor analysis, the gain could reflect technical buying (short covering, momentum traders), retail social media discussion, a press release that has not yet been picked up by aggregators, or broader market sentiment shifts in biotech. The rank of 15 biggest gainer suggests this was a genuine volume event, not a quirk of low liquidity alone.

KTWOR

K2 Capital Acquisition Corporation Rights

$0.26+$0.06

+30.0%

NASDAQ

No headlines were found in the last 48 hours explaining the 30% gain in KTWOR, a SPAC rights unit. The move likely reflects either technical trading activity, delayed news, or market sentiment shift tied to the underlying acquisition target or SPAC redemption dynamics.

K2 Capital Acquisition Corporation Rights (KTWOR) is a SPAC rights unit, a security that typically exhibits high volatility and can move sharply on relatively low volume. No news headlines were identified in the 48-hour window preceding this 30% jump, which means the catalyst is not immediately apparent from public announcements. For SPAC-related securities, price moves can be driven by several non-headline factors: changes in redemption probabilities, shifts in sentiment about the eventual merger target, unusual options activity, or short covering in a thinly traded security. Without specific news, attributing this move to a particular catalyst would be speculation. The most likely explanation is either a technical or sentiment-driven move, possibly tied to developments that haven't yet reached mainstream financial news feeds, or delayed market reaction to older information.

NE.WTA

NE-WTA

$20.50+$4.70

+29.7%

LNSR

LENSAR, Inc.Healthcare

$8.25+$1.88

+29.5%

NASDAQ · Mkt cap $107 M

LENSAR reported Q2 2026 earnings with 18% revenue growth and 10 ALLY system placements, marking a recovery in commercial momentum after the failed Alcon merger, which likely drove the strong 29.5% single-day gain.

LENSAR released Q2 2026 results on August 13, 2026 showing 18% year-over-year revenue growth and recurring revenue of $13.7 million. The company placed 10 ALLY Robotic Cataract Laser Systems in the quarter with a backlog of 13 units as of June 30, 2026. The news explicitly frames this as a continuation of rebuilding commercial momentum following the termination of the proposed Alcon merger in late Q1 2026. The combination of revenue acceleration, unit placements, and a growing backlog suggests investor confidence that the company can execute independently and that the merger termination, while initially negative, may not have materially harmed the core business trajectory. The 29.5% jump aligns with a positive earnings surprise or better-than-expected guidance relative to post-merger-failure expectations.

HCTI

Hybrid Coating Technologies, Inc.Healthcare

$1.73+$0.34

+27.9%

NASDAQ · Mkt cap $14 M

Healthcare Triangle (HCTI) surged 27.87% after reporting massive Q2 2026 earnings beats—322% gross profit increase and 158% revenue growth—signaling strong operational momentum and investor confidence in the AI-powered services business.

The company reported dramatically outsized financial results for Q2 2026, with gross profit climbing 322% and revenue up 158% year-over-year. These are exceptionally strong metrics that suggest either significant scaling of existing business, successful new customer acquisitions, or both. For a small-cap technology stock focused on AI-powered customer engagement and digital transformation, such acceleration signals market traction and operational execution. The magnitude of the beats—especially on gross profit, which indicates improved margins—likely convinced investors that the company's growth thesis is materializing. The 27.87% single-day move is proportionate to earnings surprise of this scale. No guidance revision or forward outlook was mentioned in the headline, so we don't know if management raised full-year expectations, which could have amplified the move further.

OMER

Omeros CorpHealthcare

$17.33+$3.65

+26.7%

NASDAQ · Mkt cap $1.4 B

Omeros surged 26.68% after reporting blowout Q2 earnings and revenue beats, with its flagship drug YARTEMLEA generating $28.5 million in net sales and nearly tripling quarter-over-quarter revenue, coupled with debt reduction and share buyback announcements.

Omeros reported second-quarter results that substantially exceeded analyst expectations on both earnings and revenue, with a 107.41% earnings surprise and 130.07% revenue surprise. The key driver was YARTEMLEA, a newly launched transplant complication treatment, which achieved $28.5 million in net sales for Q2 and $32.2 million in gross revenues, nearly triple the $11.1 million from Q1. This demonstrated strong commercial momentum for a recent product launch in a specialized indication. The company also announced debt reduction and share buyback initiatives, signaling financial health and management confidence. The combination of strong top-line growth, operational execution, and favorable capital allocation decisions created a comprehensive positive narrative that drove the stock to a five-year high. The magnitude of the move reflects biotech investors' enthusiasm for proven revenue traction from a commercial-stage therapeutic.

IMC

IMC Rare Earths LtdBasic Materials

$10.10+$2.10

+26.3%

NYSE · Mkt cap $1.1 B

No news headlines were found in the last 48 hours to explain IMC's 26% rally, so the driver remains unclear; the jump may reflect sector momentum, technical factors, or undisclosed developments in rare earths markets.

A 26% single-day gain for IMC Rare Earths ranks it among the top gainers, yet zero news appeared in the Yahoo Finance RSS feed over the past two days. This disconnect suggests the catalyst was either not yet widely reported through major news aggregators, occurred before the 48-hour window, or emerged through alternative channels like earnings reports, conference presentations, or regulatory filings not yet reflected in headlines. Rare earth stocks are cyclical and sensitive to commodity price movements, geopolitical supply concerns, and policy shifts around critical minerals. The absence of visible news makes it reasonable to hypothesize that the move reflects either a delayed market reaction to an earlier announcement, a sector-wide tailwind (such as rising rare earth prices or favorable legislative developments), or technical momentum.

PRHI

Presurance Holdings, Inc.Financial Services

$5.37+$1.12

+26.2%

NASDAQ · Mkt cap $25 M

Presurance Holdings jumped 26.24% on the heels of its second quarter 2026 earnings announcement on August 12, suggesting the reported results beat expectations or conveyed positive forward guidance.

The company released Q2 2026 financial results on August 12, 2026, which triggered a sharp 26% rally the next trading day. The headline excerpt is truncated and does not provide specific metrics, earnings per share, revenue figures, or management commentary, so we cannot point to the exact component of the results that drove the move. However, a 26% single-day gain following an earnings announcement typically reflects either a significant earnings or revenue beat relative to consensus, upside surprise in profitability margins, improved guidance, or positive commentary on a major business development. Without the full text of the earnings release, we cannot determine whether the driver was operational outperformance, cost savings, a new partnership, or a strategic shift in the insurance or financial services vertical. The magnitude of the move suggests the market viewed the results as materially positive.

CDTG

CDT Environmental Technology Investment Holdings Limited ordinary sharesIndustrials

$1.55+$0.32

+25.6%

NASDAQ · Mkt cap $9.9 M

No headlines were found in the last 48 hours explaining the 25.60% jump in CDTG stock, so the cause remains unknown; it could reflect delayed news, technical factors, or market sentiment shifts specific to this environmental technology investment company.

The absence of any news headlines in the 48-hour window preceding this significant gain makes it difficult to pinpoint a specific catalyst. CDTG is a small-cap environmental technology investment holding company listed on NASDAQ, and stocks of this type can experience sharp moves on limited volume due to thin trading, short covering, or delayed dissemination of company-specific announcements. Without access to press releases, SEC filings, or other formal disclosures beyond the Yahoo Finance RSS feed provided, the most likely explanations fall into broad categories: a contract award or partnership announcement not yet picked up by major news outlets, a favorable regulatory development, insider activity, or technical momentum in a stock with limited float. It is also possible that news broke outside the 48-hour window or that the move reflects accumulated market sentiment rather than a single discrete event.

A2Z Smart Technologies Corp.Technology

$8.08+$1.61

+24.9%

NASDAQ · Mkt cap $329 M

A2Z reported Q2 earnings on August 12–13 with a 73.65% revenue beat, 78% sequential revenue growth, expanded smart cart partnerships to 7,000 units, and secured a $30 million credit line, driving the +24.92% gain.

The stock rallied sharply following the release of second-quarter 2026 results. The company delivered a significant revenue surprise, beating estimates by 73.65% with reported revenue of $5.9 million. More importantly, A2Z reported strong operational momentum: sequential revenue growth of 78%, a material expansion of its key partnership to 7,000 smart carts, and the commencement of operations at its China manufacturing facility. The company also secured a $30 million credit facility, signaling financial runway to scale operations. While the company reported a net loss in the quarter, the combination of revenue acceleration, partnership expansion, and balance-sheet strengthening appears to have outweighed near-term profitability concerns. This is typical of growth-stage retail-technology companies where top-line trajectory and unit expansion often drive equity valuations.

AVAH

Aveanna Healthcare Holdings Inc.Healthcare

$11.27+$2.23

+24.7%

NASDAQ · Mkt cap $2.9 B

Aveanna Healthcare reported Q2 2026 earnings that beat both revenue and EPS estimates, posting 13.7% revenue growth and significantly higher net income, alongside revised 2026 guidance, driving the 24.67% stock surge.

On August 13, 2026, Aveanna released its Q2 earnings results showing Q2 revenue of $670.5 million (13.7% YoY growth) and net income of $40.3 million versus $27.0 million in the prior year period. The company beat EPS estimates by 29.41% and revenue estimates by 3.62%. The headlines also note higher adjusted EBITDA of $95.4 million and growth across all three operating divisions, supported by improved reimbursement rates, increased volumes, and operational efficiencies. Management provided revised 2026 full-year guidance alongside these results. The magnitude of the earnings beat, coupled with operational improvements and raised forward guidance, represents a material positive surprise that explains the 25% single-day move upward.

OPRX

OptimizeRx CorpHealthcare

$8.78+$1.72

+24.4%

NASDAQ · Mkt cap $151 M

OptimizeRx beat earnings expectations by 45% and reaffirmed full-year guidance despite a 30% revenue decline, signaling investor confidence in AI-powered products and improved profitability, driving the 24% jump.

The stock surged on the back of Q2 earnings results released on August 12-13. Although OptimizeRx reported a significant 30% year-over-year revenue drop to $20.5 million, the company delivered an earnings surprise of 45.46% and exceeded revenue estimates by 0.11%. More importantly, management maintained its full-year 2026 guidance of $95-$100 million in revenue and $21-$24 million in adjusted EBITDA despite current headwinds. The guidance reaffirmation, combined with positive leadership announcements and management commentary emphasizing AI-powered product growth and a strengthened balance sheet, appears to have reassured investors that the revenue decline is cyclical or transitional rather than structural. The adjusted EBITDA of $4.9 million demonstrates underlying profitability, which likely drove relief buying after what initially looked like a negative quarter.

AIRO

Airspan Networks, Inc.Industrials

$10.70+$2.04

+23.8%

NASDAQ · Mkt cap $271 M

AIRO reported Q2 2026 revenue of $43.2 million, up 76% year-over-year, with strong drone segment performance driving the earnings beat, which likely triggered the 23.83% single-day gain.

AIRO released second-quarter 2026 financial results on August 13, 2026, showing revenue growth of approximately 76% compared to the prior-year quarter, reaching $43.2 million. The earnings call highlights specifically note that stronger-than-expected performance in the drone segment offset weaker results in avionics and other business units. The company is described as a global leader in advanced aerospace and defense technologies. A 76% revenue increase substantially exceeds typical quarterly growth rates and represents a material positive surprise to the top line. The drone segment outperformance aligns with broader industry tailwinds in defense and commercial drone applications. The earnings release and subsequent call summary both occurred on August 13, directly coinciding with the stock's 23.83% jump, establishing a clear temporal connection between the announcement and the price move.

EXOD

EXODUS MOVEMENT INC.Technology

$6.28+$1.19

+23.4%

NYSE · Mkt cap $220 M

No news headlines were found in the last 48 hours, so the 23% gain on EXOD is unexplained by reported events; the move likely reflects technical buying, retail interest, or undisclosed company announcements not yet indexed by Yahoo Finance RSS.

The absence of any recent news headlines in the 48-hour window around this significant 23% price jump creates a data gap. EXODUS MOVEMENT INC. is a smaller-cap stock, and moves of this magnitude in micro-cap or low-volume securities can stem from several sources: technical breakouts or short covering, retail investor attention (potentially social media driven), sector rotation effects, or delayed disclosure of company news that hasn't yet propagated to major news feeds. Without access to the company's investor relations announcements, SEC filings made within the snapshot window, or confirmation of whether news was published outside the RSS feed monitored, we cannot establish a definitive catalyst. The stock's relatively low absolute price and small float are typical characteristics where outsized single-day moves can occur on modest volume or sentiment shifts.

RRGB

Red Robin Gourmet Burgers IncConsumer Cyclical

$9.89+$1.78

+21.9%

NASDAQ · Mkt cap $176 M

Red Robin reported its best traffic performance since Q1 2023 in Q2 2026 earnings, alongside $96 million in refranchising proceeds and improved comparable sales, driving a 22% stock surge on positive operational momentum and balance sheet strength.

The headlines establish that Red Robin released second-quarter 2026 results showing material operational improvements. The company achieved best traffic performance in over three years, posted comparable sales growth, improved restaurant-level margins, and announced a significant $96 million refranchising deal to bolster its balance sheet. These represent concrete positive metrics for a casual dining chain that has faced structural headwinds. The combination of renewed customer traffic, operational efficiency gains, and balance sheet relief through asset sales suggests a turnaround narrative. Investors appear to have reacted positively to evidence that management's strategy around value offerings and marketing is resonating with consumers and that the company is taking proactive steps to strengthen its financial position.

HTFL

HEARTFLOW INCHealthcare

$30.90+$6.55

+21.9%

NASDAQ · Mkt cap $4.3 B

Heartflow reported Q2 2026 financial results and raised full-year 2026 guidance on August 13, triggering a 21.94% jump as the market rewarded the company's improved outlook and likely stronger-than-expected performance.

The headline directly attributes the stock's surge to Heartflow's earnings announcement and guidance raise released on the snapshot date itself. The company reported second quarter 2026 financial results and raised full year 2026 guidance, both of which are classic catalysts that drive equity rallies when they signal operational improvement and management confidence. The timing of the news release matching the trading date, combined with the stock's rank as the 30th biggest gainer, suggests the market responded positively to the earnings outcome and forward guidance revision. While the full earnings summary and specific financial metrics are not detailed in the headline provided, the combination of reported results plus a guidance raise is sufficient to explain a double-digit percentage move in a healthcare AI company stock. No conflicting or unrelated news is evident.

FIEE

FI Enhanced Europe 50 ETN-UBSTechnology

$4.81+$0.86

+21.5%

NASDAQ · Mkt cap $40 M

No news headlines were published in the last 48 hours about FIEE, so the 21.50% gain cannot be tied to a company-specific or fund announcement. The move likely reflects broad European equity strength or a rebalancing event affecting this leveraged ETN.

FIEE is a synthetic note tracking the FI Enhanced Europe 50 Index, which uses leverage to amplify exposure to large-cap European stocks. With no recent news available, the sharp gain is most plausibly driven by one of two categories: first, a significant rally in underlying European equities (possibly driven by macroeconomic data, central bank signals, or geopolitical events) that would be mechanically amplified by the fund's leverage structure; second, technical or rebalancing activity within the ETN itself, such as a dividend reinvestment, index constituent adjustment, or mean-reversion buying after a prior drawdown. The absence of ETF-specific news reporting makes it impossible to confirm which driver dominates today's move.

MTEX

Mannatech IncConsumer Defensive

$6.15+$1.08

+21.3%

NASDAQ · Mkt cap $12 M

Mannatech reported Q2 2026 financial results on August 12, likely triggering a 21% gain if results beat expectations or signaled improved business momentum in the health and wellness sector.

The headline confirms that Mannatech released second quarter 2026 earnings on August 12, 2026, just hours before the snapshot date. The press release header is incomplete and does not provide actual financial figures, earnings per share, revenue comparisons, or management commentary that would normally explain such a sharp move. However, the timing is direct: an earnings announcement within 48 hours of a 21% jump is the most probable catalyst. The stock's strong single-day gain suggests the market responded positively to the results, though we cannot confirm whether this reflects a beat on consensus estimates, upside guidance revision, improved margins, or simply a reversal of prior weakness. Without the actual financial data or forward guidance from the release, we cannot rule out other factors like analyst upgrades or short covering, but an earnings surprise is the most parsimonious explanation given the timeline.

NCMI

National CineMedia IncCommunication Services

$2.68+$0.47

+21.0%

NASDAQ · Mkt cap $248 M

National CineMedia announced a $275 million acquisition of Captivate Network on August 11, expanding into digital out-of-home advertising, which likely drove the 21% stock surge as investors saw strategic growth and revenue diversification potential.

The headline evidence is unambiguous. On August 11, 2026, NCMI announced a definitive agreement to acquire Captivate Holdings for $275 million, a digital elevator and lobby advertising platform operated by Generation Partners. This was paired with Q2 earnings that showed 12.7% revenue growth and increased advertising sales driven by higher theater attendance. While NCMI missed EPS estimates by 11.11% and lagged revenue expectations by 3.31%, the acquisition announcement appears to have overshadowed the mixed earnings results. The deal positions NCMI as a broader digital out-of-home advertising player rather than purely a cinema-focused platform, which likely appealed to growth-oriented investors. The timing of the announcement alongside earnings creates a narrative of strategic transformation that can drive significant single-day gains in mid-cap stocks.

FFAI

Faraday Future Intelligent Electric Inc.Consumer Cyclical

$4.71+$0.81

+20.9%

NASDAQ · Mkt cap $12 M

Faraday Future announced Q2 earnings on August 13 showing record H1 revenue of $1.35 million, positive robotics margin contribution, $100 million liability reduction, and a strategic upgrade to "Four-Core Full-Stack AI," driving the 20.88% intraday gain.

The earnings announcement released after market close on August 13 appears to have been the primary catalyst for the jump. The headline metrics highlight three positive developments: record interim revenue despite the company's historical struggles, achievement of positive contribution margin in the robotics segment indicating a path toward profitability in at least one business line, and a substantial $100 million year-over-year reduction in liabilities signaling improved financial health. The strategic pivot to "Four-Core Full-Stack AI" frames a clearer long-term direction. Additionally, the August 12 stockholder meeting approvals for continued EAI robotics development may have removed uncertainty about shareholder backing. For a micro-cap EV and robotics company with limited profitability history, demonstration of revenue traction and margin improvement can trigger outsized positive reactions, particularly if prior expectations were deeply depressed.

NMTC

NeuroOne Medical Technologies CorporationHealthcare

$1.86+$0.32

+20.8%

NASDAQ · Mkt cap $19 M

NeuroOne reported Q3 2026 results with 16% year-over-year revenue growth to $2.0 million and expanding 59.9% gross margins, plus a strong order backlog of $11.2 million for fiscal 2026, likely driving the 20.78% gain as investors responded positively to revenue acceleration and margin expansion.

The earnings release published on August 13 showed concrete operational improvements: revenues grew 16% year-over-year to $2.0 million in Q3, gross margins expanded to 59.9%, and the company has accumulated $11.2 million in product orders for the full fiscal year 2026 with current shipments at $2.0 million. The order backlog exceeding shipments suggests future revenue visibility and production ramp potential. For a small-cap medical device company trading near $1.86, these metrics signal improving unit economics and growth trajectory. The stock's 20.78% jump is proportionate to the visibility these results provide for a company historically operating at modest revenue scales. No guidance changes or forward-looking statements are explicitly cited in the headlines, so we cannot determine if management raised expectations for the remainder of the year.

ONFO

Onfolio Holdings Inc. Common StCommunication Services

$2.32+$0.46

+20.1%

NASDAQ · Mkt cap $334 K

No news headlines were found in the last 48 hours for ONFO, so the 20% gain cannot be attributed to a specific disclosed catalyst; the move likely reflects technical trading, untracked social media discussion, or market sentiment shift in the micro-cap space.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means we cannot ground the explanation in a concrete disclosed event like earnings, guidance, or a strategic announcement. ONFO is a micro-cap stock trading at $2.32, a category prone to outsized moves on minimal volume and sentiment shifts. The gain could reflect several plausible but unconfirmed drivers: short covering or a squeeze narrative circulating on retail forums, technical breakout above a resistance level triggering momentum buying, a delayed press release not yet indexed by Yahoo's feed, or simply a rebalancing trade. Without access to volume data, insider activity, short interest trends, or social media chatter, attributing the move to any one cause is speculative. The lack of news coverage itself is notable and suggests the catalyst may lie outside traditional disclosure channels.

SHOTR

RMG ML Sports Holdings Rights

$0.18+$0.03

+20.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 20% gain in SHOTR (a rights offering vehicle) likely reflects a technical or structural event such as expiration dynamics, short covering, or delayed reporting of company news not yet captured in the RSS feed.

SHOTR is a rights offering security, a structural type that can exhibit sharp price movements due to leverage embedded in the rights mechanics, expiration schedules, or shifts in the value of the underlying claim. The absence of any Yahoo Finance headlines in the last 48 hours does not rule out a catalyst; news may be delayed in the RSS feed, posted on the company's investor relations channel first, or result from a technical event like redemption mechanics or short squeeze activity. Rights offerings are frequently subject to sharp moves when conversion deadlines approach or when sentiment around the parent entity shifts. Without headlines or a known catalyst timestamp, the move could reflect option expiration effects, forced buying to cover short positions, or routine bid support ahead of an event window. The stock trades at $0.18, suggesting it is a micro-cap security prone to higher volatility.

CTEV

MultiPlan CorporationHealthcare

$42.16+$6.89

+19.5%

NYSE · Mkt cap $662 M

CTEV surged 19.52% with no news headlines in the last 48 hours, so the catalyst is unclear; the move could reflect a delayed market reaction to prior announcements, technical positioning, or undetected corporate news.

No headlines were found in the last 48 hours to explain the 19.52% gain in CTEV. MultiPlan is a healthcare cost management company whose stock typically responds to earnings releases, guidance updates, contract wins, or M&A developments. The absence of recent news in the search results does not rule out that news exists—it may have been published outside the indexed sources, released after the snapshot, or announced via press release not yet picked up by RSS feeds. Alternatively, the move could reflect short covering, algorithmic rebalancing, or a delayed reaction to older announcements. Without confirmed news, the specific trigger remains unknown.

QXL

Quantum X Labs Inc.Technology

$4.60+$0.79

+19.5%

NASDAQ · Mkt cap $59 M

No news headlines were found in the last 48 hours to explain QXL's 19.51% jump, so the catalyst remains unknown; the move could stem from technical factors, delayed news not yet indexed, or market rumors unrelated to major corporate announcements.

The absence of news coverage in the provided RSS feed from Yahoo Finance over the past two days makes it impossible to identify a specific event driving QXL's substantial 19.51% gain. For a small-cap or speculative stock like Quantum X Labs, sharp moves without concurrent headline coverage often reflect technical factors such as short covering, momentum trading, or options-related activity. Alternatively, material news may have circulated through channels not captured in this RSS snapshot, or market participants may be responding to developments in the broader quantum computing sector if QXL operates in that space. Without access to the company's official announcements, SEC filings, or real-time social media discussion, attributing the move to a specific catalyst would be pure speculation.

GRDX

GridAI Technologies Corp.Healthcare

$3.74+$0.64

+19.5%

NASDAQ · Mkt cap $27 M

No news headlines were available in the last 48 hours for GRDX, so the 19.45% gain cannot be traced to a specific announced catalyst. The move likely reflects either a delayed market reaction to earlier news, technical trading, or untracked rumors.

The absence of news in the provided 48-hour window makes direct causation impossible to establish. A 19.45% single-day move in a sub-$4 stock can be driven by several common scenarios: a press release or earnings report issued before the news aggregator captured it, short-covering or retail momentum on a low-float security, broader sector rotation if GridAI operates in a hot area like AI infrastructure, or simply technical rebound after prior weakness. Without access to company filings, insider trading data, or earlier-day news sources, we cannot distinguish between these hypotheses. The stock's rank as the 40th biggest gainer suggests this was a notable but not exceptional daily move, which could indicate either legitimate news or typical small-cap volatility.

TMS

Teamshares Inc.Financial Services

$8.74+$1.44

+19.3%

NASDAQ · Mkt cap $568 M

No news headlines were found in the last 48 hours, so the 19.3% jump in TMS stock appears driven by factors other than published company announcements, likely technical or market-driven catalysts.

The absence of any news headlines in the 48-hour window preceding this significant 19.3% gain makes it difficult to pinpoint a specific catalyst. For a mid-cap stock like Teamshares trading at $8.74, such moves can occur for several reasons. The stock could have experienced a short squeeze if there was elevated short interest, a delayed reaction to an older announcement not captured in this snapshot, or a positive development in the broader market or sector that lifted smaller-cap equities. Alternatively, technical factors such as breaking above a resistance level or algorithmic buying could have contributed. Without accompanying news, we cannot rule out rumors, analyst upgrades, or insider activity, though these remain speculative. The ranking as the 41st biggest gainer suggests this was a notably strong but not extraordinary market-wide phenomenon on 2026-08-13.

ETON

Eton Pharmaceuticals IncHealthcare

$40.72+$7.89

+19.2%

NASDAQ · Mkt cap $1.7 B

Eton Pharmaceuticals surged 19.16% following strong Q2 2026 earnings announced on August 13, highlighted by record revenue of $37.6 million (99% YoY growth) and positive EPS results that exceeded typical small-cap pharma performance.

The company reported second quarter 2026 financial results showing record product sales of $37.6 million, representing 99% growth compared to the same period last year. The earnings beat was complemented by solid profitability metrics, including fully diluted GAAP EPS of $0.35 and non-GAAP EPS of $0.43, alongside EBITDA of $14.1 million and adjusted EBITDA figures that indicate operational strength. For a specialty pharmaceutical company, nearly doubling year-over-year revenue while maintaining positive earnings and double-digit EBITDA margins represents a meaningful inflection point. The market's 19% response is proportionate to these results, which demonstrate both commercial execution on existing products and financial health. The timing of the announcement on August 13 matches the stock's peak movement, establishing a direct correlation between the earnings release and the price action.

XAIR

Beyond Air IncHealthcare

$7.16+$1.11

+18.3%

NASDAQ · Mkt cap $5.1 M

Beyond Air reported Q1 2027 earnings and reaffirmed full-year revenue guidance of $8 million for 2026 and $16-18 million for 2027, likely reassuring investors on the company's path to growth and FDA PMA supplement progress for its LungFit PH system.

Beyond Air released earnings results for the quarter ended June 30, 2026 showing $1.8 million in quarterly revenue alongside a corporate update. The company reaffirmed its 2026 revenue guidance of $8 million and provided 2027 guidance of $16-18 million, representing projected doubling of revenue year-over-year. Additionally, the company noted that a PMA supplement for its second-generation LungFit PH system remains under FDA review. For a small-cap medical device company, meeting or reaffirming guidance and advancing toward FDA approval are typically positive catalysts. The 18% single-day gain suggests investor relief that the business is tracking to plan and that regulatory progress continues, though the modest absolute revenue figures underscore this remains an early-stage therapeutic company.

INAB

IN8bio IncHealthcare

$1.18+$0.18

+18.2%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours explaining INAB's 18% gain on August 13, 2026, so the catalyst remains unclear and could reflect technical trading, a delayed announcement, or market rumors.

Yahoo Finance's RSS feed returned no headlines for IN8bio Inc in the 48 hours preceding this snapshot, which makes direct attribution impossible. INAB is a clinical-stage biotech company focused on cell therapy and immunotherapy, sectors historically prone to sharp price swings on clinical trial results, regulatory decisions (FDA feedback letters, IND approvals), partnership announcements, or financing events. An 18% single-day jump in a small-cap biotech stock could plausibly stem from positive trial data, a licensing deal, a major investor entry, short covering, or algorithmic momentum trading. Without contemporaneous news, we cannot rule out delayed social media commentary, an after-hours or pre-market announcement not yet picked up by RSS feeds, or technical mean reversion in a thinly traded stock. The absence of headlines does not prove nothing happened—it suggests the catalyst may be timing-dependent or embedded in non-traditional sources.

PLRZ

Polyrizon Ltd. Ordinary SharesHealthcare

$10.75+$1.63

+17.8%

NASDAQ · Mkt cap $23 M

No news headlines were available in the last 48 hours to explain the 17.82% gain in PLRZ, so the catalyst remains unclear based on public information.

Polyrizon Ltd. experienced a significant intraday surge of nearly 18%, placing it among the top 45 gainers on NASDAQ, yet no recent news articles or press releases appear in the available feeds. This disconnect between price action and headline coverage suggests several possible explanations. The move could stem from a delayed market reaction to an announcement made earlier than the 48-hour window, internal company news not yet picked up by major financial news outlets, technical trading activity such as a short squeeze or options-related positioning, analyst upgrades not yet reflected in headline aggregators, or sector-wide positive momentum affecting smaller-cap names. Small-cap biotech and technology stocks like PLRZ often see outsized moves on limited volume and can be sensitive to social media discussion or retail trading activity that precedes formal news coverage. Without specific headlines or structural information about the company, pinpointing the precise catalyst is not possible.

WDAY

Workday IncTechnology

$206.50+$31.21

+17.8%

NASDAQ · Mkt cap $47 B

Workday surged 17.8% on August 13 following a Reuters report that private equity firm Silver Lake is in talks to acquire the company in what would be one of the largest tech buyouts ever.

Multiple news outlets published the same core story starting around 18:35 UTC on August 13: Silver Lake, a major private equity firm, is in active acquisition discussions with Workday. The headline language consistently emphasizes this would rank among the largest software or tech buyouts in history. The stock's 17.8% gain aligns with the timing of these reports, with some sources citing intraday moves of 25% at peak. This is a straightforward M&A catalyst. Workday is a major cloud-based enterprise software company with substantial revenue and market capitalization, making a Silver Lake takeover a significant corporate event. The consistent reporting across multiple financial news sources and the citation of Reuters as the original source establish this as a material disclosed development rather than speculation. No other company-specific operational or financial news is evident in the headlines.

SLGL

Sol-Gel Technologies LtdHealthcare

$83.81+$12.61

+17.7%

NASDAQ · Mkt cap $259 M

No news headlines were found in the last 48 hours, so the 17.70% gain on SLGL likely reflects a delayed market reaction to an earlier announcement, a technical or sentiment shift, or undisclosed corporate developments.

The absence of recent news in the provided feed does not rule out a catalyst; news may have broken outside the 48-hour window or on a channel not captured in this Yahoo Finance RSS snapshot. Sol-Gel Technologies is a clinical-stage dermatology and ophthalmology company, and such firms commonly see sharp moves on FDA decisions, clinical trial results, partnership announcements, or regulatory milestones. The size of the move (top 50 gainers) suggests a material event rather than pure momentum. Without headline confirmation, the cause could be a press release issued yesterday morning that has not yet propagated into this feed, an earnings or data announcement, analyst upgrade, insider activity, or short-covering. The lack of visible news does constrain confidence in pinpointing the specific driver.

INO

Inovio Pharmaceuticals IncHealthcare

$0.90+$0.13

+17.7%

NASDAQ · Mkt cap $134 M

Inovio reported Q2 2026 earnings showing narrowed net losses and FDA progress on INO-3107, plus confirmed funding runway through late Q1 2027, driving a +17.67% gain as a biotech stock approaching a potential product launch.

The headlines establish that Inovio released Q2 2026 financial results and held an earnings call on August 13, 2026. Key positives cited include a narrowed net loss (improved profitability trajectory), advancement of INO-3107 toward launch readiness, and FDA completion of several review steps on the biologics license application. The company also secured sufficient funding to extend runway into late Q1 2027, which removes near-term existential concerns about cash depletion. For a biotech company with a clinical-stage asset, news of regulatory momentum, improving cash burn, and extended runway are material positive catalysts. The timing of the earnings release and the stock's rank as the 48th biggest gainer suggest the market responded favorably to these developments as substantial validation of the company's near-term trajectory and probability of eventual commercialization.

ANGX

Angel Studios, Inc.Communication Services

$4.33+$0.65

+17.7%

INBS

Intelligent Bio Solutions Inc.Healthcare

$2.98+$0.44

+17.3%

NASDAQ · Mkt cap $8.1 M

No news headlines were found in the last 48 hours for INBS, so the 17.32% gain cannot be attributed to a disclosed catalyst. The move likely reflects technical trading, delayed news dissemination, or market speculation in a micro-cap biotech stock.

The absence of any Yahoo Finance headlines in the past two days is notable for a stock that ranks in the top 50 gainers. This does not mean nothing happened; it may mean that relevant news either has not yet been picked up by major financial RSS feeds, was announced outside the standard news window, or occurred more than 48 hours ago but is only now being priced in. For small-cap biotech companies like Intelligent Bio Solutions, catalysts typically include clinical trial results, regulatory submissions or approvals, partnership announcements, financing events, or shifts in insider holdings. Without access to company press releases, SEC filings, or social media chatter, we cannot pinpoint the specific cause. The gain could also reflect algorithmic or retail trading activity responding to chart patterns, short-covering, or unconfirmed rumors circulating among retail investors.

Biggest Losers

Thu, Aug 13, 2026 50

AACBR

Artius II Acquisition Inc. Rights

$0.00−$0.10

-99.1%

SKYH.WT

Sky Harbour Group Corporation

$0.41−$0.34

-45.3%

INV

Innventure IncFinancial Services

$3.62−$1.53

-43.1%

NASDAQ · Mkt cap $112 M

Innventure reported Q2 2026 earnings on August 13, and the 43% stock collapse suggests the results missed expectations or revealed disappointing guidance for its Accelsius thermal management product line.

Innventure released second quarter 2026 results on the same day the stock dropped 43%, making timing alignment the most likely connection. The headline references Accelsius being "focused on execution against foundational milestones to strengthen path to scaled two-phase adoption," language that suggests the company is still in early stages rather than demonstrating near-term commercial traction. For an industrial technology company, this phrasing could signal slower-than-expected adoption, margin pressure, or delayed revenue ramp that disappointed investors betting on faster scaling. The incomplete news snippet provided does not include actual financial metrics, guidance revision, or explicit reasons for underperformance, so the precise nature of the miss cannot be confirmed from the evidence given. The second headline about SKYX appears unrelated to INV and likely appeared in a broad market news feed.

LESL

Leslie''s IncConsumer Cyclical

$0.77−$0.52

-40.3%

NASDAQ · Mkt cap $6.1 M

Leslie's reported Q2 earnings on August 12 that missed analyst revenue expectations with an 8.4% year-over-year sales decline and EPS significantly below forecasts, plus the company withdrew full-year guidance and announced it is exploring strategic alternatives, triggering a 40%+ stock collapse.

The headlines establish that Leslie's released Q2 2026 earnings after market close on August 12, missing on both top and bottom lines. Revenue fell to $458.5 million, down 8.4% year-over-year and below consensus. Non-GAAP EPS of $3.96 came in 21.8% below expectations. Most critically, the company withdrew its full-year guidance and announced it is exploring strategic alternatives for its balance sheet. These actions signal management believes the operational environment is deteriorating faster than previously communicated and that the business may require restructuring. The earnings call highlights mention a 6.2% comparable sales decline and note that e-commerce growth and customer reactivation efforts are underway, but these positives were overwhelmed by the negative guidance withdrawal and strategic review announcement, which typically implies potential dilution, asset sales, or worse outcomes ahead.

FGL

Founder Group Limited Ordinary SharesIndustrials

$0.50−$0.28

-36.2%

NASDAQ · Mkt cap $475 K

FGL dropped 36% despite announcing a $1.4 million aquaculture solar contract on August 12, suggesting the market either found the deal disappointing relative to expectations or reacted to negative sentiment unrelated to this specific news.

The company announced a legitimate business win—a second aquaculture contract valued at $1.4 million for a 1.78 MW rooftop solar system in Malaysia—on August 12, yet the stock fell sharply the following day. This disconnect between positive operational news and a severe price decline suggests several possibilities. The market may have viewed the contract size as insufficient or margins as weak relative to prior guidance or peer benchmarks. Alternatively, the drop may reflect broader sector headwinds in renewable energy or Malaysia-focused risks, or it could indicate that negative sentiment or guidance from management accompanied the announcement in the full press release but was not captured in the headline excerpt provided. A third possibility is that the stock was already under selling pressure from technical factors, short positions, or other catalysts and the contract announcement failed to arrest the decline. Without access to full earnings metrics, guidance, or management commentary, the precise trigger remains unclear.

MVIS

MicroVision IncTechnology

$3.78−$1.46

-31.5%

NASDAQ · Mkt cap $42 M

MicroVision announced a proposed public offering on August 13, which typically triggers sharp selloffs due to dilution concerns and increased share supply hitting the market.

The headline confirms that MicroVision announced a proposed public offering on the same day as the 31.53% drop. Public offerings are a well-documented catalyst for stock declines, especially in smaller-cap technology names like MVIS. The mechanism is straightforward: existing shareholders face dilution from new shares being issued, and the market often discounts the stock ahead of and during offerings to reflect the increased supply. The timing alignment between the announcement date and the largest single-day loss suggests this offering announcement is the primary driver. Without additional details on offering size, use of proceeds, or pricing, we cannot assess whether the market's reaction was proportionate, but the causality chain is clear.

AMPG

Amplitech Group Inc.Technology

$6.00−$1.95

-30.5%

NASDAQ · Mkt cap $107 M

AmpliTech reported strong Q2 earnings with 50.9% sequential revenue growth and 161% gross profit expansion, yet the stock crashed 30.54%, suggesting the market either expected even stronger results, cited forward guidance concerns, or reacted to factors not disclosed in the headline excerpt.

The earnings announcement itself contains objectively positive headline metrics: revenue of $8.07 million up 50.9% sequentially and gross profit up 161.2% year-over-year, with margin expansion to 27.9% from 7.8%. These are not earnings misses. The massive sell-off despite positive earnings typically indicates one of three scenarios: guidance was reduced or absent, profitability or cash flow failed to materialize despite gross margin gains, or the stock had risen so sharply pre-earnings that the market viewed even strong results as priced in and disappointing relative to expectations. Without the full earnings statement, details on net income, operating expenses, guidance, or commentary on demand trends, we cannot determine which factor drove the decline. This type of disconnect between headline metrics and stock reaction is common in small-cap stocks prone to high volatility and sentiment swings.

CLBT

Cellebrite DI Ltd.Technology

$10.82−$4.52

-29.5%

NASDAQ · Mkt cap $2.9 B

Cellebrite reported Q2 earnings and revenue that missed estimates, delayed large transactions, and cut 2026 revenue guidance, prompting a leadership change and triggering the 29.5% plunge.

Cellebrite DI delivered mixed results on August 13, 2026. The company missed both earnings (surprise of -8.33%) and revenue estimates (surprise of -1.30%) for Q2 ended June 2026. More critically, the earnings call revealed delays in large customer transactions, slower-than-expected pricing power, and weaker customer expansion gains. Management attributed headwinds partly to heightened cloud and AI procurement competition. The company subsequently cut full-year 2026 revenue guidance downward. A leadership change was also announced. For a digital forensics software vendor, missing revenue targets and reducing forward guidance signals either loss of competitiveness, extended sales cycles, or macro weakness in government and law enforcement spending. The magnitude of the single-day decline (-29.54%) reflects investor disappointment in both the miss and the reduced outlook, typical of high-multiple software stocks when growth expectations contract materially.

SECZ

Securitize Corp.Technology

$5.68−$2.27

-28.6%

NYSE · Mkt cap $1.2 B

No news headlines were found in the last 48 hours for Securitize Corp., so the 28.55% drop cannot be directly attributed to a specific announced catalyst. The decline likely reflects either a delayed market reaction to older news, technical selling pressure, or an undisclosed event.

The absence of recent news makes attribution difficult. Securitize operates in the blockchain and tokenization space, sectors that can experience sharp price swings based on regulatory sentiment, sector-wide momentum shifts, or individual company developments. A 28.55% single-day drop of this magnitude in a smaller-cap stock typically requires either a material negative announcement, a sharp technical breakdown, or broader sector capitulation. Without headlines, this could reflect delayed reaction to earnings or guidance from earlier in the week, selling pressure tied to a sector downturn, or a private development that has not yet reached public news feeds. Institutional redemptions, short covering reversals, or momentum-driven exits in a thinly traded security can also produce outsized single-day losses.

TSSI

TSS, Inc.Technology

$11.98−$3.19

-26.4%

NASDAQ · Mkt cap $266 M

TSS Inc. reported Q2 2026 earnings on August 13 showing strong 46% year-over-year Systems Integration revenue growth, but the 26% stock decline suggests the market judged the results or forward guidance as disappointing relative to expectations.

TSS released second-quarter financial results on the same day as the sharp drop, which is the most direct catalyst available. The headline emphasizes positive metrics: Systems Integration revenue grew 46% YoY and now represents 39% of total revenue at ~$17 million, plus the company is investing $17 million to drive future AI Data Center Technology revenue. However, the magnitude of the single-day decline (26%) despite these headline growth figures suggests either the overall earnings and revenue missed analyst expectations, full-year guidance was lowered, or margins disappointed. Without access to the full earnings report, consensus estimates, or management commentary, the precise earnings miss or guidance shortfall cannot be pinpointed. The fact that a smaller competitor (MPTI) also missed earnings the prior day could reflect sector-wide headwinds, though that alone does not explain TSS's sharp move.

OBX

Obsidian Therapeutics, Inc.Healthcare

$19.04−$6.84

-25.5%

VERI

Veritone IncTechnology

$1.47−$0.38

-24.7%

NASDAQ · Mkt cap $97 M

Veritone reported Q2 2026 earnings and cost reduction updates on August 13, triggering a 24.68% sell-off, suggesting the results or guidance disappointed market expectations despite a partnership announcement the prior day.

The earnings announcement from Veritone on August 13 is the most proximate catalyst for the sharp 24.68% decline. While the headline itself does not disclose specific financial metrics, earnings misses or disappointing guidance typically drive such sharp single-day moves in small-cap stocks. The company framed the release around "cost reductions," which may signal margin pressure or revenue challenges rather than growth momentum. Notably, a partnership announcement with ZeroEyes the prior day did not prevent the decline, suggesting investors focused more on the quarterly fundamentals than the partnership value. Without access to the actual Q2 numbers, guidance, or analyst consensus expectations, the precise nature of the disappointment cannot be confirmed, but the timing and magnitude point directly to the earnings event as the driver.

RKDA

Arcadia Biosciences IncConsumer Defensive

$0.55−$0.18

-24.6%

NASDAQ · Mkt cap $964 K

Arcadia announced solid Q2 results including improved cash burn and July Zola sales exceeding $1 million monthly, yet the stock fell 24.6%, suggesting the market may have expected stronger financial performance or greater cash position despite the operational progress.

The news headline highlights genuine operational improvements—net cash burn of only $319K in Q2, a successful $4 million private placement, and strong monthly Zola sales momentum crossing $1 million. These are materially positive metrics for a small biotech company. However, the stock dropped sharply on the day of announcement, which typically suggests either the full earnings release contained disappointing guidance, a lower-than-expected cash runway despite recent fundraising, unfavorable development updates on pipeline programs not mentioned in the headline snippet, or market expectations had already priced in this level of performance. Without access to the complete earnings release, guidance statements, or analyst consensus, the exact source of disappointment cannot be pinpointed. Small-cap biotech stocks are often volatile around earnings regardless of headline quality, responding to subtle changes in cash burn trajectory, upcoming milestones, or competitive positioning.

CBRG

Chain Bridge IFinancial Services

$5.16−$1.58

-23.4%

WYTC

WYTEC INTERNATIONAL INC

$1.31−$0.39

-22.9%

NASDAQ

WYTEC International fell 22.94% on August 13 with no news headlines identified in the last 48 hours, making the specific catalyst unclear.

No relevant news headlines were found in the last 48 hours to explain this sharp 22.94% decline. For a micro-cap stock trading at $1.31, price moves of this magnitude can be triggered by several categories of events: delayed earnings announcements or missed guidance, regulatory developments, shareholder dilution or capital raises, insider selling, technical liquidation from stop-loss orders, or negative commentary on social media or investment forums. Without access to current news beyond the Yahoo Finance RSS feed provided, or knowledge of WYTEC's recent earnings calendar, insider activity, or market sentiment, any specific explanation would be speculative. The stock's low price and ranking as the 15th biggest loser suggests this was a material adverse move affecting investor confidence.

IMDX

Insight Molecular Diagnostics Inc.Healthcare

$3.72−$0.97

-21.6%

NASDAQ · Mkt cap $143 M

No material negative news was released in the past 48 hours; the 21.6% decline likely reflects broader market weakness, technical selling, or undisclosed company-specific developments not captured in the available headlines.

The only recent news available is a positive announcement on August 11 regarding an upcoming virtual KOL event on August 17 about heart transplant organ rejection testing, which should theoretically be neutral to slightly positive for investor sentiment. The sharp 21.6% drop occurred after this announcement, suggesting the market decline is not grounded in the disclosed headline. For a small-cap molecular diagnostics company trading at $3.72, typical catalysts for sharp single-day losses include clinical trial setbacks, regulatory delays, cash burn concerns, or insider selling that may not immediately appear in public headlines. It is also possible that broader market conditions, sector rotation out of biotech, or technical breakdown of a chart pattern drove selling pressure. Without additional news sources or context, the true catalyst remains unclear.

HTZ

Hertz Global Holdings IncIndustrials

$2.35−$0.62

-21.5%

NASDAQ · Mkt cap $809 M

Pershing Square Capital Management, a major shareholder, exited its entire stake in Hertz on August 13, citing a botched equity offering announced in June. The high-profile exit triggered the 21.5% single-day plunge as investor confidence collapsed.

The news is unambiguous and contemporaneous with the stock collapse. Bill Ackman's Pershing Square had held a material position in Hertz and publicly announced its exit on August 13, explicitly blaming management's June equity offering as mishandled. The fund noted Hertz was one of its worst performers year-to-date, subtracting 1.1% from gross performance. The timing of the exit announcement coinciding exactly with the 21.5% drop, combined with the explicit criticism of the equity offering and broader concerns about Hertz's balance sheet health mentioned in the August 11 reporting, strongly suggests this institutional capitulation was the proximate trigger. The departure of a named, credible large investor carries outsized signaling weight in a stock already trading at a low share price where retail sentiment had been driving recent volatility.

FLYX.WT

flyExclusive, Inc.

$0.15−$0.04

-21.1%

SLND

Southland Holdings, Inc.Industrials

$0.55−$0.15

-21.0%

NYSE · Mkt cap $32 M

Southland Holdings reported Q2 earnings that missed revenue estimates by 33% and posted a large loss, triggering a 21% stock decline on the poor financial performance.

Southland released Q2 2026 results on August 12 that included a significant revenue miss of 33% versus expectations and a substantial earnings shortfall of 192%, delivering a net loss for the quarter. The company simultaneously announced a financing agreement and credit amendment with Surety Partners on August 13, suggesting liquidity or financial stress. The combination of disappointing earnings, the need to restructure credit facilities, and weak revenue performance provides a clear fundamental reason for the sharp selloff. The stock's ranking as the 19th biggest loser on the day aligns with a market repricing of the company's operational and financial trajectory based on these disclosed quarterly results.

BSEM

BioStem Technologies, Inc.Healthcare

$3.10−$0.82

-20.9%

NASDAQ · Mkt cap $60 M

BioStem reported strong Q2 revenue growth and raised full-year guidance on August 12, yet the stock fell 20.87% the next day, suggesting the market may have focused on the reported net loss, the $10M milestone payment obligation, or manufacturing transition execution risks that outweighed the rev…

The headlines establish that BioStem delivered a 23.43% revenue beat ($7.9M, up 29% sequentially) and raised full-year guidance, which would normally support a stock price. However, the same news also disclosed a $10M milestone payment and a planned manufacturing transition, both of which carry execution and cash-flow risk. The company reported a net loss for the quarter, which the headlines flag explicitly. For a small-cap biotech or medical-device company with limited cash reserves, a $10M outflow combined with ongoing losses could have triggered a reassessment of runway and dilution risk. The Nasdaq uplisting is positive but does not offset concerns about profitability trajectory or near-term cash needs. The disconnect between revenue beat and price drop suggests investors either (a) were expecting a narrower loss or profitability, or (b) reacted negatively to the disclosed obligations and transition risks.

LFTO

Liftoff Mobile, Inc.Communication Services

$20.06−$5.19

-20.6%

NASDAQ · Mkt cap $3.2 B

Liftoff Mobile reported Q2 earnings and held its first public earnings call on August 12-13, but the 20.56% drop suggests the market's expectations were not met, likely due to disappointing guidance, margins, or growth rates relative to IPO enthusiasm.

The news headlines confirm that Liftoff Mobile released Q2 2026 financial results and held an earnings call as a newly public company. The headlines mention revenue growth and expanded adjusted EBITDA margins, which sound positive on the surface. However, the magnitude of the sell-off (rank 21 biggest loser, down over 20%) indicates the market reacted negatively to details disclosed during or after the earnings call. This is typical behavior when a recently IPO'd company reports results that fall short of inflated post-IPO expectations, or when management provides forward guidance that disappoints. Without access to the full earnings report, guidance statements, or analyst commentary, the specific shortfall cannot be pinpointed, but the timing of the headlines directly preceding the stock's decline strongly suggests the earnings release and call were the primary catalysts.

REZI

Resideo Technologies IncIndustrials

$20.47−$5.27

-20.5%

NYSE · Mkt cap $3.0 B

Resideo plunged 20% despite beating Q2 earnings and revenue estimates and completing a spin-off, likely because full-year sales guidance came in significantly below expectations, signaling weakness in forward demand.

The headlines present a mixed picture that resolves into one clear negative catalyst. Resideo reported better-than-expected Q2 earnings and revenues, completed the spin-off of its ADI Global Distribution business on August 3, and appointed a new CFO—all typically positive developments. However, one headline explicitly states that while Q2 sales beat, the company's full-year sales guidance missed expectations significantly. Forward guidance misses tend to trigger sharp sell-offs because they signal deteriorating business momentum ahead, overriding near-term beat sentiment. The 20% single-day drop is consistent with a guidance miss in a cyclical industrial/home automation name where investors price in growth expectations. The Q2 beat appears insufficient to offset the cautionary outlook.

SKYQ

Sky Quarry Inc.Energy

$2.72−$0.69

-20.2%

NASDAQ · Mkt cap $12 M

Sky Quarry Inc. fell 20.23% on August 13, 2026, with no news headlines found in the last 48 hours, making the specific catalyst impossible to identify from available sources.

The absence of any news from Yahoo Finance RSS in the last 48 hours means no confirmed catalyst—earnings, guidance, regulatory action, partnership announcements, or other material events—can be linked to this drop. A stock of this size (trading near $2.72) could move sharply on several unstated triggers: a delayed press release not yet indexed by the news feed, technical selling pressure following a previous rally, a rumor or social media discussion, insider trading activity ahead of an announcement, broader market sector weakness in quarrying or materials, or adverse developments disclosed through channels other than mainstream business news. Without access to the company's investor relations feed, SEC filings, or real-time trading data, we cannot narrow the cause further. The rank as the 23rd biggest loser suggests broad market participation in the sell-off rather than isolated weakness.

OTLK

Outlook Therapeutics IncHealthcare

$0.89−$0.22

-20.1%

NASDAQ · Mkt cap $167 M

Outlook Therapeutics announced a $55 million public offering of 55.6 million shares at a 10% discount, causing dilution-driven selling pressure that resulted in a 20% drop.

The headlines directly identify the catalyst: on August 12-13, Outlook Therapeutics announced and priced a public offering of common stock and warrants totaling $55 million. The offering was priced at a 10% discount to the prior day's closing price, which is a significant concession that typically signals capital urgency or weak demand. Large secondary offerings dilute existing shareholders' ownership and are often viewed negatively by the market, particularly in small-cap biotech where cash burn is a concern. The timing of the pre-market crash on August 13 aligns precisely with the pricing announcement, establishing a clear cause-and-effect relationship. No competing news about clinical trial results, regulatory decisions, or other company-specific developments is mentioned, so the offering appears to be the dominant driver of the -20.12% move.

ATXG

Addentax Group CorpIndustrials

$3.94−$0.96

-19.6%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours, so the cause of the 19.59% drop cannot be attributed to a reported announcement or event. The decline likely resulted from technical selling, market-wide pressure, or unreported news.

Without any recent headlines to anchor the analysis, the sharp 19.59% single-day decline in ATXG cannot be directly attributed to a specific corporate event such as earnings, guidance, regulatory action, or M&A. Small-cap stocks like Addentax Group are particularly susceptible to intraday volatility driven by technical factors, shifts in sentiment among retail traders, or news that has not yet surfaced in major financial media feeds. It is also possible that a material announcement was made but not yet indexed by the RSS feed used here, or that the decline reflects broader sector weakness or idiosyncratic trading activity. Without corroborating information, any specific cause remains speculative.

BIAF

bioAffinity Technologies, Inc. Healthcare

$0.38−$0.09

-19.0%

NASDAQ · Mkt cap $3.3 M

bioAffinity Technologies announced a $4M at-the-market private placement offering on August 13, which typically dilutes existing shareholders and likely triggered the 19% single-day sell-off.

The company priced a $4M private placement offering at-the-market under Nasdaq rules on the same day as the stock's sharp decline. At-the-market offerings allow companies to sell shares at prevailing market prices, creating immediate dilution risk and negative sentiment among existing shareholders who fear value destruction. The timing of the announcement (13:07 UTC) aligns with the trading session, and the magnitude of the decline (19%) is consistent with typical market reaction to equity dilution events, particularly for lower-priced, lower-liquidity microcap stocks like BIAF trading at $0.38. The headlines do not disclose the number of shares issued or the specific terms beyond the $4M raise amount, but the dilutive effect of equity financing is a known and immediate negative catalyst for biotechnology companies with limited market capitalization.

CEPL

Capstone Energy Plus, Inc.Industrials

$6.71−$1.54

-18.6%

NASDAQ · Mkt cap $204 M

Capstone Energy+ reported a 10.8% year-over-year revenue decline in Q1 fiscal 2027 due to lower product shipment volume and reduced rental activity, triggering an 18.62% stock price drop on August 13, 2026.

The earnings announcement on August 12 disclosed that quarterly revenue fell from $27.9 million to $24.9 million, with the company explicitly citing lower product shipment volume and reduced rental revenue as drivers of the decline. This represents a material contraction in top-line performance that the market has interpreted negatively. The stock's 18.62% single-day drop ranks it among the day's 27 biggest losers, suggesting investors either expected stabilization or growth and were disappointed by the weakness, or that underlying demand conditions for microturbine energy solutions have deteriorated more than previously communicated. Without access to guidance updates, margin performance, or management commentary on forward outlook, it is unclear whether this is cyclical weakness or a sign of structural challenges in the company's market.

BIVI

BioVie Inc.Healthcare

$1.57−$0.34

-18.6%

NASDAQ · Mkt cap $10 M

No news headlines were found in the last 48 hours, so the 18.58% drop cannot be attributed to a specific announced event. The decline likely reflects either a delayed market reaction to earlier news, technical selling, or a company-specific development not yet picked up by major news feeds.

BioVie is a small-cap biotech stock, and the complete absence of recent headlines makes pinpointing a specific catalyst difficult. Biotech stocks in this size category are sensitive to clinical trial results, regulatory decisions, financing announcements, and partnership developments, all of which can drive sharp single-day moves. The magnitude of the decline (18.58%) suggests something material, but without corroborating news it is impossible to confirm whether this was triggered by an earnings disappointment, trial setback, dilutive financing, insider selling disclosure, short covering, or purely technical momentum reversal. The lack of coverage in the Yahoo Finance RSS feed within 48 hours does not rule out a company press release or SEC filing that simply has not been widely indexed yet.

SSTI

ShotSpotter IncTechnology

$8.40−$1.50

-18.4%

NASDAQ · Mkt cap $81 M

ShotSpotter (now SoundThinking) slashed full-year revenue guidance from $109-111M to $99-100M and cut adjusted EBITDA margin guidance to 8-9%, triggering an 18.4% stock decline on the earnings report.

The company reported Q2 2026 results accompanied by materially lower full-year guidance. The revenue reduction of approximately $10M (roughly 9% of the midpoint) and compressed margin outlook represent a significant downward revision that investors interpret as a deterioration in business momentum or demand outlook. For a smaller-cap software/services company trading on profitability metrics, margin compression combined with revenue miss signals either competitive pressure, customer churn, or operational challenges. The market's 18% selloff is proportionate to the magnitude of the guidance cut and suggests investors were not forewarned of this weakness, making it a genuine surprise to the market.

DGNX

DIGINEX LIMITEDIndustrials

$1.52−$0.30

-18.1%

NASDAQ · Mkt cap $37 M

Diginex announced 77% revenue growth and three strategic acquisitions on the same day as an update on the Resulticks acquisition proposal, yet the stock fell 18.1%, suggesting market skepticism about execution risk, dilution concerns, or broader sell-off pressure unrelated to the news.

The company released genuinely positive headlines on August 13—revenue growth of 77%, debt-free status, and completion of three cross-border acquisitions to scale its ESG/sustainability compliance platform. These are typically bullish signals. However, the stock dropped sharply the same day, which creates a disconnect. Possible explanations: (1) investors may be concerned about dilution from the acquisitions or the pending Resulticks deal, (2) the market may doubt the company's ability to execute on multiple simultaneous integrations, (3) the announcement may have triggered profit-taking in a stock that had run up prior, (4) there may be unrelated negative technical or sector-wide pressure on small-cap compliance software stocks, or (5) the details of the Resulticks acquisition update on August 12 may have contained concerning terms not evident from the headline alone. Without the full text of these announcements or trading volume context, the cause remains partially obscured.

CAST

FreeCast, Inc. Class ACommunication Services

$1.00−$0.22

-18.0%

NASDAQ · Mkt cap $100 M

No news headlines appeared in the last 48 hours for CAST, so the 18% decline likely reflects either a delayed market reaction to an earlier announcement, technical selling pressure, or sector-wide weakness in streaming or media stocks.

FreeCast is a small-cap streaming and digital media company trading at $1.00, making it susceptible to sharp moves on low volume and minimal news flow. The absence of any headlines in the past 48 hours does not rule out a catalyst; the move could be a delayed reaction to news from earlier in the week, or it could reflect technical factors common to penny-range stocks such as position liquidation, short covering reversals, or sector rotation out of unprofitable digital media plays. Without confirmed news, the most probable categories are either an undisclosed or delayed-reporting company development, broader sector headwinds affecting streaming platforms, or algorithmic/technical selling in a thinly-traded security. The ranking as 31 biggest loser suggests the move is material and stock-specific rather than purely random noise.

SPEGR

Silver Pegasus Acquisition Corp Rights.

$0.23−$0.05

-17.9%

NASDAQ

No news headlines were found in the last 48 hours, so the 17.86% drop in this SPAC rights offering cannot be attributed to a specific announced event. The decline likely reflects either technical selling, broader market weakness in blank-check securities, or deteriorating sentiment around the und…

Silver Pegasus Acquisition Corp Rights (SPEGR) is a SPAC rights offering, a security that typically trades on sentiment around the sponsor's acquisition prospects and the broader SPAC market environment. With no headlines published in the last 48 hours, the decline cannot be tied to company-specific news such as a failed merger announcement, target withdrawal, or regulatory setback. Rights offerings in SPACs are particularly sensitive to redemption risk and market perception of deal viability. A 17.86% single-day drop in a low-priced rights unit could reflect a shift in market expectations about the deal closing or investor redemptions, or it could be driven by broader weakness in SPAC-related securities. Without current news, the most probable categories are technical selling pressure, a delayed announcement becoming public through other channels, or macroeconomic factors affecting blank-check appetite.

SNYR

Synergy CHC Corp.Healthcare

$0.11−$0.02

-17.7%

NASDAQ · Mkt cap $1.6 M

No news related to SNYR was provided in the headlines; the 17.75% drop on August 13 cannot be explained by the single unrelated NeuroPace (NPCE) earnings item in the feed.

The only headline provided is about NeuroPace, Inc. (NPCE), a different company entirely, and reports on their Q2 earnings results—not SNYR. This headline does not account for Synergy CHC's sharp intraday decline. Without news specific to SNYR, the drop could reflect several typical catalysts for micro-cap stocks: unannounced earnings disappointment or guidance cut, insider selling or lock-up expiration, sector rotation out of healthcare or medical devices, a delayed press release not yet indexed by the feed, or general market pressure on low-liquidity equities. Given SNYR trades at $0.11 (penny-stock territory), volatility is expected and can be driven by thin volume swings, technical breaks, or rumors not yet appearing in major news sources.

WisdomTree Euro Debt FundEnergy

$1.14−$0.24

-17.1%

NASDAQ · Mkt cap $210 M

There is a ticker symbol mismatch in the provided data. The stock listed as EU on NASDAQ is WisdomTree Euro Debt Fund, but the news headlines reference enCore Energy Corp., which also trades under ticker EU. Without clarity on which security actually moved, the cause cannot be determined.

The data presents a critical ambiguity. WisdomTree Euro Debt Fund (EU) is a fixed-income ETF focused on euro-denominated debt, while the three news items all reference enCore Energy Corp., a uranium and clean energy company, also trading under NASDAQ ticker EU. These are entirely different securities with different fundamentals. If the price move belongs to the ETF, it would likely stem from eurozone credit spreads, duration shifts, or currency dynamics unrelated to the nuclear energy sector. If it belongs to enCore Energy, the Q2 earnings report and the controlled equity offering announcement could explain the drop, as secondary offerings typically dilute shareholders and earnings reports may have disappointed. The 17% single-day drop is dramatic for an ETF tracking a broad debt index but plausible for an equity issuer announcing dilution alongside financial results.

APURR

Aperture AC Rights

$0.18−$0.04

-17.1%

NASDAQ

No news was found in the last 48 hours, so the 17% drop cannot be attributed to a published headline; the cause is likely technical selling, delayed market reaction to an earlier event, or unconfirmed market rumors.

The stock APURR declined 17.09% to $0.18 on August 13, 2026, but no news headlines were available in the preceding 48 hours on Yahoo Finance. This absence of recent published catalysts makes it difficult to pinpoint a specific driver. For a micro-cap stock trading at $0.18 with minimal public disclosure, common causes of sharp single-day moves include technical capitulation (stop-loss cascades), short-covering reversals, liquidity events tied to fund redemptions or margin calls, or delayed market reaction to information released via non-traditional channels or in earlier periods not captured in this snapshot. Rights-bearing securities like APURR sometimes move sharply on corporate actions or shareholder dilution concerns, though no such announcement appears in the available data.

BAOS

Baosheng Media Group Holdings Limited Ordinary sharesCommunication Services

$0.62−$0.13

-17.0%

NASDAQ · Mkt cap $799 K

No news headlines were found in the last 48 hours, so the 16.99% drop cannot be attributed to a specific disclosed event; the cause likely falls into technical selling, delayed announcements, or sector-wide pressure.

The absence of any news in Yahoo Finance's RSS feed over the last 48 hours means we cannot identify a specific catalyst for BAOS's sharp 16.99% decline. For a small-cap stock trading at $0.62 on NASDAQ, price swings of this magnitude can occur due to several structural factors: thin trading liquidity leading to outsized moves on modest volume, delayed disclosure of material news (earnings, regulatory action, or insider transactions that may not yet be widely published), sector rotation or broader market weakness affecting smaller-cap media holdings, short covering or short accumulation, or technical breakdown through a support level. Without access to real-time order flow, insider trading filings, or after-hours developments, we cannot distinguish among these possibilities.

HUMA

Humacyte, Inc.Healthcare

$0.55−$0.11

-16.9%

NASDAQ · Mkt cap $157 M

Humacyte reported Q2 2026 earnings that missed revenue estimates by 71% and showed a net loss of $36.8 million on just $0.406 million in sales, alongside Nasdaq compliance pressure, driving the 16.89% decline despite positive Phase 3 dialysis trial data.

The headline evidence points to a classic biotech earnings miss scenario. Humacyte reported Q2 revenue of $0.406 million versus estimates, missing by 70.79%, and reported a net loss of $36.8 million. The company faces Nasdaq compliance pressure, suggesting it may be below minimum listing standards. While the company announced encouraging Phase 3 dialysis access results and plans a supplemental BLA filing, these forward-looking catalysts appear insufficient to offset the severe near-term commercial underperformance and cash burn reality. The stock has already fallen 93% over the past five years, and current valuations are described as expensive relative to book value despite the recent decline. The earnings shortfall and regulatory pressure likely triggered forced selling or rebalancing today.

SMTK

SmartKem, Inc.Technology

$0.11−$0.02

-16.7%

NASDAQ · Mkt cap $2.2 M

SmartKem announced an executive appointment to its subsidiary Ferrox on the same day the stock fell 16.67%, but the news itself is routine and does not explain the sharp decline; the drop likely reflects broader market factors, investor sentiment, or undisclosed information.

The only headline provided is a routine executive appointment announcement—Allen Palmiere joining Ferrox as Executive Director and Chief Operating Officer. This type of personnel news is typically neutral to mildly positive and does not ordinarily trigger a 16.67% single-day drop in a stock. The appointment may have been overshadowed by other developments not captured in the headlines provided, such as negative earnings or guidance revision, sector rotation out of small-cap semiconductor or materials firms, short-term technical selling, or broader market volatility. Without additional context on SmartKem's recent financial performance, cash position, or competitive standing, the executive appointment alone cannot reasonably explain the magnitude of the decline. The stock's rank as the 38th biggest loser suggests the move was part of a broader sell-off pattern rather than a company-specific catalyst directly tied to the news released.

APMCR

AmperCap Acquisition Company Right

$0.10−$0.02

-16.7%

NASDAQ

No news headlines were found in the last 48 hours, so the 16.67% decline cannot be attributed to a specific announced event; the drop likely reflects technical selling or market conditions typical of blank-check acquisition vehicles.

AmperCap Acquisition Company Right (APMCR) is a SPAC rights unit, a security type that often exhibits high volatility and low trading liquidity. The absence of any news in the provided headlines means we cannot point to a specific catalyst such as a merger announcement, regulatory filing, or business update. SPACs and their components trade on deal momentum and redemption activity, so declines can occur from general market weakness, redemption pressure, loss of deal confidence, or technical factors like rebalancing or tax-loss selling. Without headlines or context about pending deals or company news, the precise cause remains unclear, though illiquid micro-cap securities in this category are prone to sharp moves on relatively modest volume.

BSP

Bending Spoons S.p.A.Technology

$40.76−$8.13

-16.6%

NASDAQ · Mkt cap $26 B

Bending Spoons reported Q2 revenue and operating income that beat analyst expectations, yet shares fell 16.62%, suggesting investors either faced disappointment on guidance, margins, or forward outlook despite the earnings beat.

The headlines confirm that Bending Spoons announced Q2 2026 results on August 13, with revenue of $704 million (beating the pre-announced analyst expectation of $683 million) and operating income of $240 million. The company also reported an earnings beat. However, the stock fell sharply despite these positive results, which is atypical and points to negative guidance, margin compression concerns, or other forward-looking warnings not detailed in the available headlines. One headline explicitly states "Bending Spoons Shares Slip Despite Q2 Earnings and Revenue Beat," confirming the disconnect. The earnings call details, management commentary on growth trajectory, capital allocation plans, or any reduced forward guidance are not provided in these headlines, leaving the precise reason for the sell-off unclear.

TPR

Tapestry IncConsumer Cyclical

$128.42−$25.15

-16.4%

NSYS

Nortech Systems IncHealthcare

$12.75−$2.46

-16.2%

NASDAQ · Mkt cap $34 M

Nortech reported strong Q2 earnings with record margins and 9.3% revenue growth on August 12-13, yet the stock fell 16.17%, suggesting the market either found guidance disappointing, encountered a large sell-off unrelated to the earnings substance, or had already priced in the positive results.

The headlines confirm Nortech released second-quarter 2026 results on August 12 with notable operational achievements: record gross margins and a 9.3% revenue increase attributed to nearshoring and technology investments. The earnings call highlights frame this as clearly positive. However, the stock declined sharply on the same day and into August 13. This disconnect between positive earnings and a significant stock drop is unusual but not unprecedented. Possible explanations include: the company issued conservative forward guidance that disappointed despite current-quarter strength, the market had already fully priced in these results before the announcement, or a broader market rotation or sector-specific headwind affected small-cap manufacturers. Without access to full guidance commentary or conference call transcript details beyond the headlines provided, we cannot isolate whether the weakness stems from expectations management, valuation concerns, or external market factors unrelated to fundamentals.

BRAG

Bragg Gaming Group Inc.Consumer Cyclical

$1.51−$0.28

-15.6%

NASDAQ · Mkt cap $46 M

Bragg Gaming Group reported Q2 2026 earnings on August 13, and the stock fell 15.64%, suggesting the results or forward guidance disappointed investors, though the specific metrics are not detailed in the headlines provided.

The earnings call summary and financial results announcement were both released on August 13, 2026, the same day as the sharp decline. This timing strongly implies the earnings report triggered the sell-off. However, the headlines provided do not specify whether the disappointment stemmed from missed revenue or profit targets, lowered guidance, margin compression, regulatory headwinds, or weakened forward commentary. Bragg operates in the competitive igaming and gaming platform space, where investor sentiment is sensitive to user growth, revenue per user, profitability transitions, and competitive positioning. Without access to the actual earnings metrics, commentary, or guidance revision, we can infer that at least one material metric fell short of consensus expectations or raised concerns about the company's near-term trajectory.

LWAY

Lifeway Foods IncConsumer Defensive

$24.69−$4.50

-15.4%

NASDAQ · Mkt cap $378 M

Lifeway Foods reported record Q2 revenues of $66.9M, up 24.1% year-over-year, but the 15.4% stock drop suggests investors reacted negatively to guidance, margins, or other forward-looking metrics not detailed in the headlines provided.

The news headlines document strong top-line results with record quarterly net sales and growth in core kefir and Farmer Cheese products. However, a 15.4% single-day decline following an earnings announcement typically reflects disappointment in profitability, guidance, or margin trends rather than revenue growth alone. The headlines provided focus exclusively on sales figures and do not mention earnings per share, gross margin, operating income, cash flow, or management guidance for future quarters. This omission is critical: a company can deliver record revenue while simultaneously disappointing investors through lower-than-expected net income, reduced guidance, or margin compression. The magnitude of the decline suggests the market reacted to something materially negative beyond the revenue beat, most likely either earnings per share falling short of expectations or cautious forward guidance.

AOSL

Alpha & Omega Semiconductor LtdTechnology

$30.75−$5.53

-15.2%

NASDAQ · Mkt cap $745 M

Alpha & Omega reported better-than-expected Q4 revenue and significantly improved gross margins with strong AI server growth guidance, yet the stock fell 15.24%, suggesting the market either priced in rosier expectations or reacted to an unmentioned factor such as guidance, valuation concerns, or…

The headlines from August 12-13 establish that Alpha & Omega delivered a revenue beat of 1.41% and an earnings surprise of 43.48% on August 12. The company reported improved gross margins of 200 basis points, record advanced computing revenue, and a 60% AI server growth outlook. These are materially positive developments that would normally support a stock price gain, yet AOSL fell sharply the next trading day. The disconnect suggests either (a) the market had already priced in stronger results and found the guidance or commentary underwhelming, (b) management's forward-looking statements or margin expectations disappointed despite the beat, or (c) the decline reflects a separate catalyst not captured in the headlines provided, such as a competitive announcement, analyst downgrade, or sector rotation away from semiconductor equipment makers.

GXAI

The NFT Gaming Company, Inc.Communication Services

$1.26−$0.22

-15.2%

NASDAQ · Mkt cap $9.2 M

GXAI fell 15.17% despite Gaxos reporting record Q2 revenue up 1,337% year-over-year, suggesting the market either discounted the results in advance, concerns exist about valuations or forward guidance, or a broader sector selloff in gaming/NFT/AI stocks occurred.

The headline announces a significant earnings beat with record sequential and year-over-year revenue growth, plus improving unit economics (revenue per advertising dollar). This would typically support a stock price, yet GXAI dropped sharply, ranking as the 46th biggest loser of the day. This disconnect suggests either that (a) the market had already priced in strong results and sold on the news anyway, a common pattern with high-growth stocks, (b) forward guidance or commentary on profitability and cash runway disappointed despite top-line strength, or (c) broader headwinds in the gaming, NFT, or AI sectors dragged down the stock independent of company-specific results. Without the full earnings release, conference call tone, or guidance, we cannot isolate which factor drove the decline.

ABEO

Abeona Therapeutics IncHealthcare

$6.35−$1.12

-15.0%

NASDAQ · Mkt cap $349 M

Abeona reported Q2 earnings with ZEVASKYN revenue growth of 31% to $11.4 million, but the stock fell 15% likely due to disappointing patient treatment volume (only 5 patients in Q2, 3 to date in Q3) and manufacturing constraints that missed investor expectations.

The headlines confirm Abeona reported second-quarter results on August 13 with positive headline revenue growth for its ZEVASKYN cell therapy product. However, the earnings call highlights explicitly mention operational challenges involving patient scheduling and manufacturing that affected revenue realization. The company has completed only 12 treatments since launch despite the product being on the market, suggesting a significant ramp constraint. While 31% quarter-over-quarter revenue growth sounds positive, the absolute patient treatment numbers appear to be well below what investors anticipated for a commercial product in its growth phase. This disconnect between percentage growth and actual throughput—combined with cited manufacturing bottlenecks—likely triggered the sell-off as investors downwardly revised their patient acquisition and revenue projections.

IEAGR

Infinite Eagle Acquisition Corp. Rights

$0.17−$0.03

-14.9%

NASDAQ

No news headlines were available in the last 48 hours to explain the 14.91% drop in IEAGR shares, making the cause unclear without additional context or market data.

The absence of recent news makes direct attribution impossible. IEAGR is a rights offering unit from Infinite Eagle Acquisition Corp, a blank-check entity. Rights typically trade on thin volume and are sensitive to sentiment shifts around the underlying SPAC's merger prospects, redemption activity, or broader market moves in microcap acquisition vehicles. The decline could reflect negative headlines about the sponsor or target company that haven't yet appeared in the Yahoo Finance feed, technical selling in a low-liquidity instrument, or a shift in merger probability or deal terms. Rights are also subordinated instruments that lose value quickly as expiration approaches if the deal faces uncertainty. Without seeing the actual catalyst, we cannot distinguish between fundamental deterioration in deal prospects versus routine volatility in a thinly-traded security.

GITS

Hanryu Holdings, Inc.Communication Services

$1.79−$0.31

-14.8%

NASDAQ · Mkt cap $6.2 M

GITS fell 14.84% with no news headlines in the last 48 hours, making it impossible to identify a specific catalyst from available information.

No headlines were found in the last 48 hours on Yahoo Finance RSS, so there is no news-based explanation available for the decline. For a micro-cap stock like Hanryu Holdings trading at $1.79, price moves of this magnitude can be driven by several categories of factors: technical selling in illiquid names, delayed news from an earlier window that has now circulated more widely, insider transactions or short-seller activity, changes in market sentiment toward a particular sector, or company-specific events that have not yet reached major news wires. Without additional context about the company's sector, recent earnings dates, or institutional ownership, any explanation beyond "no reported catalyst" would be pure speculation.

IPDN

Professional Diversity Network IncIndustrials

$0.24−$0.04

-14.8%

NASDAQ · Mkt cap $2.7 M

No news headlines were reported in the last 48 hours for IPDN, so the 14.82% drop cannot be directly attributed to a specific announced event. The decline likely reflects broader market weakness, technical selling, or undisclosed company developments.

Yahoo Finance returned no headlines for IPDN in the past 48 hours, eliminating direct news-based causation as an explanation. Professional Diversity Network Inc is a small-cap stock trading at $0.24, which makes it susceptible to price volatility driven by technical factors, liquidity constraints, or rumor-based selling that may not generate major news coverage. Possible causes include: (1) sector-wide selling or broader market pullback affecting small-cap equities, (2) a technical breakdown or stop-loss cascade after the stock declined below a key price level, or (3) company-specific information circulating informally or on message boards that has not yet reached mainstream financial news wires. Without corresponding headlines or official announcements, determining the precise catalyst remains speculative.